

Contents

List of Contributors XV

1	Medicinal Inorganic Chemistry: State of the Art, New Trends, and a Vision of the Future	1
	<i>Nicola J. Farrer and Peter J. Sadler</i>	
1.1	Introduction	1
1.1.1	Metals in the Body: Essential Elements and Diseases of Metabolism	6
1.1.2	Metals as Therapeutic Agents	6
1.2	Antimicrobial Agents	8
1.3	Antiviral Agents	15
1.4	Systemic and Metabolic Diseases Including Inflammation	18
1.4.1	Diabetes and Obesity	18
1.4.2	Metal Homeostasis and Related Diseases	19
1.5	Metal Chelating Agents	19
1.6	Antiarthritic Drugs and Inflammation	21
1.7	Bipolar Disorder	22
1.8	Anticancer Agents	22
1.8.1	Pt ^{II} Cytotoxic Agents	23
1.8.2	Pt ^{IV} Prodrugs	24
1.8.3	Photoactivatable Pt ^{IV} Complexes	25
1.8.4	Ruthenium	25
1.8.4.1	Interaction with Plasma Proteins	25
1.8.4.2	Ruthenium Arenes	26
1.8.5	Osmium	29
1.8.6	Titanium	29
1.8.7	Gold	31
1.8.8	Tin	32
1.8.9	Gallium	33

Bioinorganic Medicinal Chemistry. Edited by Enzo Alessio
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
ISBN: 978-3-527-32631-0

1.8.10	Arsenic	33
1.8.11	Copper	34
1.8.12	Zinc	34
1.8.13	Bismuth	34
1.8.14	Molybdenum	35
1.8.15	Photosensitizers: Porphyrins	35
1.9	Small Molecule Delivery and Control	35
1.9.1	Nitric Oxide (NO)	35
1.9.2	Carbon Monoxide (CO)	36
1.10	Diagnostic Agents	36
1.11	Veterinary Medicinal Inorganic Chemistry	37
1.12	Conclusions and Vision	37

2 Targeting Strategies for Metal-Based Therapeutics 49

Julia F. Norman and Trevor W. Hambley

2.1	Introduction	49
2.2	Physiological Targeting	49
2.2.1	Antitumor Drugs Targeting Tumor Hypoxia	50
2.2.2	Antitumor Drugs Targeting Vascular Structure	54
2.2.3	Antitumor Drugs Targeting Tumor pH	54
2.2.4	Light Activated Prodrugs	55
2.3	Molecular Targeting	57
2.3.1	Protein and Peptide Targeting	57
2.3.1.1	Protein Receptor Binding	57
2.3.2	Peptide Tethering	63
2.3.2.1	Directing Effects	64
2.3.3	Selective Activation	65
2.3.4	DNA Targeting	66
2.3.4.1	Duplex DNA Sequence Selectivity	66
2.3.4.2	Telomeric Targeting	68
2.4	Immunological Targeting	69
2.4.1	Antigen Targeting	70
2.4.2	Antibody Tethering	71
2.5	Concluding Remarks	73

3 Current Status and Mechanism of Action of Platinum-Based Anticancer Drugs 79

Shanta Dhar and Stephen J. Lippard

3.1	Introduction	79
3.1.1	Platinum Chemotherapy and Cancer	79
3.1.2	Palette of Current Platinum Chemotherapeutic Drugs	79
3.1.3	Early History of Cisplatin and Approved Platinum Drugs for the Clinic	82
3.2	Mechanism of Action of Cisplatin	82
3.2.1	Cisplatin Accumulation	82
3.2.2	Cisplatin Activation	82

3.2.2.1	Binding to DNA Targets	83
3.2.2.2	Binding to Non-DNA Targets	84
3.2.3	Cellular Processing of Platinum-DNA Adducts	84
3.2.3.1	Cytotoxicity Associated with High Mobility Group (HMG) Proteins	85
3.2.3.2	Cytotoxicity Associated with Non-HMG Proteins	86
3.3	Limitations of Current Platinum-Based Compounds: New Strategies	87
3.4	Novel Concepts in the Development of Platinum Antitumor Drugs	87
3.4.1	Functionalized Single-Walled Carbon Nanotubes (SWNTs) as Vehicles for Delivery of Pt(IV)-Prodrugs	88
3.4.2	Targeted Nanoparticles for Delivery of Cisplatin for Prostate Cancer	89
3.4.3	Gold Nanoparticles as Delivery Vehicles for Platinum Compounds	90
3.4.4	Delivery of Pt(IV) Compounds Targeting Cancer Cell Metabolism	91
3.5	Concluding Remarks	93
4	New Trends and Future Developments of Platinum-Based Antitumor Drugs	97
	<i>Xiaoyong Wang and Zijian Guo</i>	
4.1	Introduction	97
4.2	Mechanisms of Action and Resistance	99
4.2.1	Mechanism of Action	99
4.2.2	Mechanism of Resistance	100
4.2.2.1	Decreased Drug Accumulation	100
4.2.2.2	Increased Detoxification	101
4.2.2.3	Enhanced Repair and Increased Tolerance to DNA Damage	101
4.2.2.4	Reduced Apoptotic Response and Activation of Survival Pathways	102
4.3	Monofunctional Platinum(II) Complexes	103
4.4	Trans-Platinum(II) Complexes	107
4.5	Multinuclear Platinum(II) Complexes	114
4.6	Platinum(IV) Complexes	124
4.7	Delivery of Platinum Drugs	130
4.8	Concluding Remarks and Future Perspectives	139
5	Ruthenium and Other Non-platinum Anticancer Compounds	151
	<i>Ioannis Bratsos, Teresa Gianferrara, Enzo Alessio, Christian G. Hartinger, Michael A. Jakupiec, and Bernhard K. Keppler</i>	
5.1	Introduction	151
5.2	Ruthenium Anticancer Compounds	152

5.2.1	Chemical Features of Ruthenium Compounds	152
5.2.2	<i>Trans</i> -[tetrachloridobis(1 <i>H</i> -indazole)ruthenate(III)] Complexes and their Development	153
5.2.3	Ruthenium-dmso Compounds: The Development of NAMI-A	156
5.2.3.1	Chemical Features of NAMI-A	157
5.2.3.2	NAMI-A-Type Complexes	158
5.2.3.3	Mechanism of Action of NAMI-A	159
5.2.4	Half-Sandwich Ru-Organometallics	160
5.2.4.1	Piano-Stool Ru-Arene Compounds	160
5.2.4.2	RAPTA Compounds	162
5.2.4.3	Other Half-Sandwich Ru Compounds	163
5.3	From Gallium Nitrate to Oral Gallium Complexes	164
5.4	Titanium Anticancer Compounds	165
5.4.1	Budotitane: The First Transition Metal Complex in Clinical Trials in the Post-cisplatin Era	165
5.4.2	Titanocene Dichloride and Related Compounds	166
5.5	Ferrocene-Derived Anticancer Agents	166
5.6	The Main Group Organometallics Spirogermanium and Germanium-132	167
5.7	Arsenic in Cancer Chemotherapy	168
5.8	Overcoming the Resistance of Tumors to Anticancer Agents by Rare Earth Element Compounds	169
5.9	Conclusions	170
6	The Challenge of Establishing Reliable Screening Tests for Selecting Anticancer Metal Compounds	175
	<i>Angela Boccarelli, Alessandra Pannunzio, and Mauro Coluccia</i>	
6.1	Introduction	175
6.2	Tumor Cell Growth Inhibition and Cell Death Screening Assays	177
6.3	Metal-Based Anticancer Compounds and Gene Expression Microarray Technologies	181
6.3.1	Basal Transcription Profiling and Sensitivity/Resistance to Metal-Based Anticancer Drugs	183
6.3.2	Profiling Gene Expression Alterations in Response to Treatment with Metal-Based Anticancer Drugs	185
6.4	Metal-Based Anticancer Compounds and the Proteomic Approach	187
6.5	Concluding Remarks	190
6.5.1	Cytotoxic Metal-Based Anticancer Agents	190
6.5.2	Non-Cytotoxic Metal-Based Anticancer Agents	190
6.5.3	Tumor-Targeted Metal-Based Anticancer Agents	191
6.5.4	Towards a Global Mechanistic-Based Screening Approach	191

7	Gold-Based Therapeutic Agents: A New Perspective	197
	<i>Susan J. Berners-Price</i>	
7.1	Introduction	197
7.1.1	An Historical Perspective	197
7.1.2	Current Interest in Gold-Based Drugs	199
7.2	Biological Chemistry of Gold	200
7.2.1	Gold(I) Oxidation State	200
7.2.2	Gold(III) Oxidation State	202
7.3	Gold Antiarthritic Drugs	202
7.3.1	Structural Chemistry and Biotransformation Reactions	202
7.3.2	Mode of Action	204
7.4	Gold Complexes as Anticancer Agents	205
7.4.1	Gold(I) Compounds	205
7.4.1.1	Auranofin and Related Compounds	205
7.4.1.2	Tetrahedral Gold(I) Diphosphines and Related Compounds	206
7.4.1.3	Gold(I) N-Heterocyclic Carbene Compounds	209
7.4.2	Gold (III) Compounds	210
7.4.3	Mode of Action of Gold-Based Anticancer Drugs	212
7.5	Gold Complexes as Antiparasitic Agents	214
7.6	Concluding Remarks	215
8	MRI Contrast Agents: State of the Art and New Trends	223
	<i>Daniela Delli Castelli, Eliana Gianolio, and Silvio Aime</i>	
8.1	Introduction	223
8.2	T ₁ Agents	224
8.2.1	Theory of Paramagnetic Relaxation	224
8.2.2	Clinically Approved T ₁ Agents	227
8.2.2.1	Paramagnetic Gd(III)-Based Complexes	227
8.2.2.2	Mn(II)-Based Complexes	229
8.2.3	Preclinical Level	230
8.2.3.1	ECF Agents	230
8.2.3.2	Blood Pool Agents	231
8.2.3.3	Responsive T ₁ Agents	232
8.3	T ₂ -Susceptibility Agents	234
8.3.1	Iron Oxide Particles	235
8.3.2	Paramagnetic Liposomes	235
8.4	CEST Agents	236
8.4.1	Theoretical Background	237
8.4.1.1	The Sensitivity Issue	239
8.4.2	Paramagnetic CEST Agents: PARACEST	241
8.4.2.1	Responsive PARACEST Agents	244
8.4.2.2	Cell Labeling	248
8.5	Concluding Remarks	249

9	Metal-Based Radiopharmaceuticals	253
	<i>Roger Alberto</i>	
9.1	Introduction	253
9.1.1	Selection of the Radionuclide	254
9.1.2	Production of Radionuclides	255
9.1.3	Concepts and Chemistry of Labeling	258
9.1.4	Different Generations of Metal-Based Radiopharmaceuticals	260
9.2	Selected Examples: Therapeutic Radiopharmaceuticals	262
9.2.1	The “3 + Family”: Yttrium and Some Lanthanides	262
9.2.2	Rhenium	265
9.2.3	α -Emitters: Bismuth and Actinium	267
9.3	Diagnostic Metal-Based Radiopharmaceuticals	269
9.3.1	The “3 + Family Continued”: Indium and Gallium	269
9.3.2	Technetium	272
9.3.3	Targeted Radiopharmaceuticals: Technetium-Labeled Carbohydrates	274
9.3.4	Technetium-Essential Radiopharmaceuticals for Heart Imaging	276
9.4	Perspectives and Conclusion	278
10	Boron and Gadolinium in the Neutron Capture Therapy of Cancer	283
	<i>Ellen L. Crossley, H. Y. Vincent Ching, Joseph A. Ioppolo, and Louis M. Rendina</i>	
10.1	Introduction	283
10.2	Boron Neutron Capture Therapy	284
10.2.1	Key Criteria for BNCT Agents	285
10.2.2	Clinical BNCT Agents	286
10.3	Role of Medicinal Inorganic Chemistry in BNCT	287
10.3.1	Platinum–Boron Agents	288
10.3.2	Boronated Porphyrins	289
10.3.3	Boronated Phosphonium Salts	290
10.3.4	Radiolabeling of Boronated Agents for <i>In Vivo</i> Imaging	291
10.3.5	Radiofluorination of BPA	292
10.3.6	Carborane Radiohalogenation	292
10.3.7	Radiometallacarboranes	293
10.4	Gadolinium Neutron Capture Therapy	294
10.4.1	Archetypal Gd NCT Agents	295
10.4.2	Hybrid Boron–Gadolinium Agents	296
10.5	Conclusions and Future Outlook	297

11	Essential Metal Related Metabolic Disorders	307
	<i>Yasmin Mawani and Chris Orvig</i>	
11.1	Introduction: What is Essentiality?	307
11.2	Iron Metabolic Diseases: Acquired and Genetic	307
11.2.1	Iron Homeostasis	307
11.2.2	Diseases of Primary Iron Overload: Hemochromatosis	309
11.2.2.1	Type 1 Hereditary Hemochromatosis	309
11.2.2.2	Type 2 Hereditary Hemochromatosis: Juvenile Hemochromatosis	309
11.2.2.3	Type 3 Hereditary Hemochromatosis	311
11.2.2.4	Type 4 Hereditary Hemochromatosis: African Iron Overload	311
11.2.2.5	Neonatal Hemochromatosis	311
11.2.3	Diseases of Iron Overload: Accumulation of Iron in the Brain	311
11.2.3.1	Aceruloplasminemia	312
11.2.3.2	Hallervorden–Spatz Syndrome (HSS)	312
11.2.3.3	Friedreich’s Ataxia	312
11.2.4	Acquired Iron Overload Disorders	313
11.2.5	Treatment of Iron Overload Disorders: Chelation Therapy	313
11.2.6	Iron Deficiency	314
11.3	Copper Metabolic Diseases	315
11.3.1	Copper Homeostasis	315
11.3.2	Copper Deficiency: Menkes Disease	317
11.3.3	Copper Overload: Wilson’s Disease	318
11.3.4	Treatment of Wilson’s Disease: Chelation Therapy	318
11.4	Zinc Metabolic Diseases	319
11.4.1	Zinc Homeostasis	319
11.4.2	Zinc Overload: Zinc Toxicity	321
11.4.3	Treatment of Zinc Toxicity: Chelation Therapy	321
11.4.4	Acquired Zinc Deficiency	322
11.4.5	Genetic Zinc Deficiency: Acrodermatitis Enterophathica	322
11.5	Diseases Related to Imbalances in Electrolytic Metabolism: P, the Alkali Metals, and the Alkaline Earths	323
11.5.1	Sodium	324
11.5.1.1	Hyponatremia	326
11.5.1.2	Hypernatremia	327
11.5.2	Magnesium	328
11.5.2.1	Hypomagnesemia	328
11.5.2.2	Hypermagnesemia	329
11.5.3	Potassium	330
11.5.3.1	Hypokalemia	330
11.5.3.2	Hyperkalemia	331
11.5.4	Phosphorus	332
11.5.4.1	Hypophosphatemia	333

11.5.4.2	Hypophosphatasia	334
11.5.4.3	Hyperphosphatemia	335
11.5.5	Calcium	336
11.5.5.1	Vitamin D	336
11.5.5.2	Parathyroid Hormone	337
11.5.5.3	Hypocalcemia	337
11.5.5.4	Hypercalcemia	337
11.5.5.5	Diseases Related to the Parathyroid Hormone	338
11.5.5.6	Hyperparathyroidism (HPT)	339
11.5.5.7	Osteomalacia	340
11.5.5.8	Milk-Alkali Syndrome	340
11.5.5.9	Calcifying Disorders	340
11.6	Metabolism of Other Trace Elements	341
11.6.1	Questionable Essentiality of Nickel, Molybdenum, and Vanadium	341
11.6.1.1	Nickel	341
11.6.1.2	Molybdenum	342
11.6.1.3	Vanadium	342
11.6.2	Chromium	343
11.6.3	Cobalt and Vitamin B ₁₂	344
11.6.4	Manganese	344
11.6.5	Selenium	345
11.7	Conclusions	346

12 Metal Compounds as Enzyme Inhibitors 351

Gilles Gasser and Nils Metzler-Nolte

12.1	Introduction	351
12.2	Kinase Inhibitors	352
12.3	Proteasome Inhibitors	354
12.4	Carbonic Anhydrase Inhibitors (CAIs)	355
12.5	Cyclooxygenase Inhibitors	358
12.6	Acetylcholinesterase Inhibitors	361
12.7	Protein Phosphatase Inhibitors	362
12.8	Trypsin and Thrombin Inhibitors	363
12.9	Cysteine Protease Inhibitors and Glutathione Transferase Inhibitors	365
12.10	HIV-1 Reverse Transcriptase and Protease Inhibitors	368
12.11	Telomerase Inhibitors	369
12.12	Zinc Finger Protein Inhibitors	372
12.13	CXCR4 Inhibitors	372
12.14	Xanthine Oxidase Inhibitors	374
12.15	Miscellaneous Protein Inhibitors and Conclusions	374

13	Biomedical Applications of Metal-Containing Luminophores	383
	<i>Albert Ruggi, David N. Reinhoudt, and Aldrik H. Velders</i>	
13.1	Introduction: Luminescence in Diagnostics and Imaging	383
13.2	Transition-Metal Containing Luminescent Agents	386
13.2.1	Photophysical Properties of Transition Metal Complexes	386
13.2.2	Ruthenium(II) Complexes	388
13.2.2.1	DNA Binding	388
13.2.2.2	Protein Binding	390
13.2.2.3	Cell Staining	390
13.2.3	Iridium(III) Complexes	391
13.2.4	Rhenium(I) Complexes	392
13.2.5	Platinum(II) Complexes	393
13.2.6	Other Metal Complexes	393
13.3	Lanthanide-Based Luminophores	394
13.3.1	Chemical and Photophysical Properties of Lanthanide Complexes	394
13.3.2	Europium(III) and Terbium(III) Complexes	396
13.3.2.1	Immunoassays	396
13.3.2.2	Nucleic Acid Probes	398
13.3.2.3	Molecular Imaging	398
13.3.3	Neodymium(III) and Ytterbium(III) Complexes	399
13.4	Nanoparticle-Based Luminophores	399
13.4.1	Chemical and Photophysical Properties of Luminescent Nanoparticles	399
13.4.2	Semiconductor Quantum Dots	400
13.4.3	Metal-Doped Nanoparticles	402
13.5	Conclusions and Perspectives	402
	Index	407